

August 26, 2025



## Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:

- **Citi's 2025 Biopharma Back to School Conference in Boston, MA**  
Rigel will participate in one-on-one meetings on Tuesday, September 2.
- **Cantor Global Healthcare Conference 2025 in New York, NY**  
Rigel will participate in one-on-one meetings and present a company overview on Wednesday, September 3, at 8:35 a.m. ET.
- **2025 Wells Fargo Healthcare Conference in Boston, MA**  
Rigel will participate in one-on-one meetings on Thursday, September 4.
- **H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference in New York, NY**  
Rigel will participate in one-on-one meetings and present a company overview on Tuesday, September 9, at 1:30 p.m. ET.

To access the live webcasts or archived recordings of the Cantor and H.C. Wainwright Conference presentations, visit the Investor Relations section of the company's website at [www.rigel.com](http://www.rigel.com). Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

### **About Rigel**

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit [www.rigel.com](http://www.rigel.com).

### **Contact for Investors & Media:**

#### **Investors:**

Rigel Pharmaceuticals, Inc.

650.624.1232

[ir@rigel.com](mailto:ir@rigel.com)

**Media:**

David Rosen

Argot Partners

646.461.6387

[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



View original content to download multimedia:<https://www.prnewswire.com/news-releases/rigel-to-participate-in-upcoming-september-investor-conferences-302538238.html>

SOURCE Rigel Pharmaceuticals, Inc.